We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK’s Trelegy Ellipta Fails to Get Asthma Indication in Europe
GSK’s Trelegy Ellipta Fails to Get Asthma Indication in Europe
GlaxoSmithKline (GSK) should not be allowed to add an allergy indication to its European Medicines Agency (EMA) marketing authorization for Trelegy Ellipta (fluticasone furoate, umeclidinium and vilanterol), the agency’s Committee for Medicinal Products for Human Use (CHMP) decided last week.